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Introduction
Coenzyme Q10 (CoQ10; 2,3-dimethoxy-5-methyl-6-polipropenyl-
1,4-benzoquinone), also known as ubiquinone 10, is a lipophilic naturally 
occurring compound located in all membranes of eukaryotic organisms 
[1]. It is a benzoquinone with 10 isoprene units in the aliphatic chain [2] 
and it is essential for electron transfer in the mitochondrial respiratory 
chain, playing a key role in energy metabolism as an integral part of the 
electron transport system [3,4]. CoQ10 is the predominant ubiquinone 
species in humans and it originates from endogenous biosynthesis as 
well as from dietary intake. It is widely distributed in human tissues, 
especially in inner membranes of mitochondria where it affects their 
fluidity and permeability [3,5]. It plays a key role in maintaining the 
cellular redox state and acts as an antioxidant, inhibiting free radicals 
and showing synergism with other antioxidants [6].
CoQ10, found in most dairy products, vegetables, fruit and cereals 
has been studied as an antioxidant agent that protects circulating 
lipoproteins against oxidative damage [7] and it is recognized as a 
powerful systemic antioxidant that protects DNA, lipids and proteins 
against oxidative damage. In fact CoQ10 has been recognized to be useful 
in prophylaxis and therapy of various disorders related to oxidative 
stress, such as cardiovascular diseases [8,9], neurodegenerative diseases 
[10-12] and mitochondrial disease [13].
CoQ10 is a key factor in the aging process and the maintenance of 
this nutrient is a good strategy to preserve health during aging [14,15]. 
CoQ10 deficiency syndromes are potentially treatable disorders [16-
18]. Immediate diagnosis leads to better prevention and correction 
of the clinical symptoms. CoQ10 deficiency can also be associated 
to a high risk of development of chronic diseases [19,20], such as 
heart failure, hypertension [21-23], neurodegenerative disorders, 
and diabetes [24]. CoQ10 can be supplied by diet, and its content 
is higher in animal products than in plant products [25,26]. Meat, 
fish, and vegetable oils are good sources of CoQ10, while vegetables, 
fruits, and cereals are a very poor source. It has been demonstrated 
that the oral intake of CoQ10 may also improve functional capacity 
and endothelial function in chronic heart failure [8] without any side 
effects. For these reasons in the last few years, the number of CoQ10 
dietary supplements has increased rapidly. Several analytical methods 
have been developed for the determination of CoQ10 content, based 
on spectrophotometric, colorimetric [27], electrochemical [28,29] and 
electrophoretic techniques [30], but the method of choice is reversed 
phase high performance liquid chromatography (LC) with ultraviolet 
detection [31,32], electrochemical detection [33-35] or tandem mass 
spectrometry detection (MS/MS) [36,37]. The more recent reports 
deals with the development of miniaturized LC/UV systems [38] 
and the demonstration of the effect of CoQ10 in the reduction of the 
oxidative stress and of the inflammatory markers [39,40]. Moreover 
a study on the in vivo oxidation of CoQ10 was carried out [41]. The 
extensive scientific production in this field demonstrates that there is 
a great interest in CoQ10 due to its important physiological activities.
In this paper we developed and validated a UPLC/MS-MS method, 
based on a liquid-liquid extraction procedure, for the determination 
of CoQ10 in human plasma, which differentiates from the other 
methods because of the rapidity of extraction and the fast analytical 
times requested. The method was optimized using another endogenous 
substance, CoQ9, as Internal Standard (IS). CoQ9 is present in human 
plasma at not significant concentrations or at least its low amount 
does not influence its use as IS at the concentrations required for the 
analyses (Figure 1). 
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Abstract
To evaluate CoQ10 concentration a UPLC/MS-MS method for its analysis in plasma samples was developed. 
Before validation, the choice of the anticoagulant, of the Internal Standard (CoQ9; IS) and the stability of CoQ10 
in plasma were evaluated. These determinations were necessary to assess the effect of the oral intake of CoQ10 
in nine healthy volunteers after 10 days of treatment with a food supplement containing it. The basal levels of 
CoQ10 were determined and the analyses were repeated after four days to take into account the variability of 
endogenous substances. After oral intake, the increase in plasma concentration of CoQ10 resulted statistically 
significant (P<0.05), indicating that the assumption of food supplements containing this ubiquinone could be of help 
to increase its concentration, thus exploiting the its beneficial properties. 
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(IS, CoQ9) are shown in Table 1.
The transitions from 863.60 to 197.17 and from 795.49 to 197.11 
were chosen for the quantification of CoQ10 and CoQ9 respectively.
Statistical analysis
Statistical differences of data were examined by using the Student’s 
t test, calculated by Microsoft Excel software.
Optimization of the Analytical Method
Choice of the Internal Standard (IS)
CoQ9 is an endogenous ubiquinone structurally related to CoQ10; 
it was chosen as an internal standard because it is not detectable in the 
small amount of plasma used for the analysis (250 µL), due to its low 
concentration in human plasma or at least its low amount does not 
influence its use as IS at the concentrations required for the analyses; 
therefore it does not interfere in the quantification of the analytes. 
Moreover it is well separated from CoQ10 (Figures 1a and 1b).
Choice of the anticoagulant
To be stored and analysed plasma samples have to be treated 
with an anticoagulant. We evaluated three different anticoagulants 
The method was applied to the analysis of CoQ10 in the plasma 
of nine healthy volunteers, assuming for 10 days food supplements 
containing it, in order to evaluate the increase of ubiquinone 
concentration in plasma after oral intake. The basal levels were assessed 
considering two withdrawals carried out four days away from one 
another to take into account the variability of endogenous analytes. 
Moreover the best anticoagulant and the best storage conditions were 
evaluated.
Materials and Methods
Chemicals, reagents and standards
Coenzyme Q10, coenzyme Q9 (IS), methanol, acetonitrile and 
hexane were obtained from Sigma Aldrich (Germany); ethanol was 
supplied from Fluka (Germany). All reagents were of analytical grade 
and were stored as required by the manufacturer. Water (18.2 mΩ/
cm) was prepared by a Milli-Q System (Millipore, France). Quality 
control (QC) samples were prepared in physiological solution at a 
concentration of 100 ngtot to test the performance of the analytical 
method.
Plasma samples
For the stability test of CoQ10, five plasma samples supplied by 
the Centro Diagnostico Italiano (CDI) from five healthy volunteers 
were taken into account. For the evaluation of the increment of CoQ10 
concentration before and after the oral intake of food supplements 
containing CoQ10, 9 healthy volunteers were treated with a food 
supplement containing CoQ10 (16 mg) with high solubility (Eufortyn 
10 FL 15 ML, 130 mg) for 7 consecutive days. Plasma was taken 
before the treatment and at the end of the treatment. Analyses were 
carried out in triplicate, considering the median value among the three 
determinations. 
Liquid-liquid (L-L) extraction method
Plasma (250 µL) was added with IS (100 µL, 1 µg/mL), methanol 
(400 µL) and extracted with hexane (1 mL). The mixture was put on 
a rotary shaker (15 min, 15 rpm) and then centrifuged (5 min, 5000 
rpm). The supernatant was withdrawn and the solvent evaporated. 
The residue was stored in the refrigerator (4°C) in vials wrapped in 
aluminium foil to prevent degradation caused by light and dissolved in 
acetonitrile (200 µL) before LC analysis.
LC/MS-MS analysis
The analyses were performed on ACQUITY H (Quaternary 
Solvent Manager) LC/MS-MS system, equipped with a ACQUITY 
(Sample Manager-FTN) tray cooled auto-sampler and a ACQUITY 
(TQ Detector) triple quadrupole mass spectrometer.
Chromatographic separation was performed at 40°C on a C18 
ACQUITY UPLC BEH C18 1.7 μm 2.1 × 50 mm (Waters) column. 
The mobile phase consisted of a 90/10/0.1 mixture of acetonitrile/2-
propanol/formic acid in isocratic elution mode. Flow rate: 0.4 mL/min. 
Injection volume: 10 μL.
Ionization was achieved using electrospray in the positive mode 
(ESI+); needle voltage: +3100 V; shield voltage: +30 V; source 
temperature: 150°C; drying gas (N2) flow rate: 600 L/h; drying gas 
(N2) temperature: 450°C. Multiple Reaction Monitoring (MRM) 
modes were chosen for the detection, using Argon at a flow rate of 20 
L/h as CID gas. 
The MRM transitions selected for CoQ10 and the internal standard 
 
Figure 1a: Chromatogram of a plasma sample in which CoQ9 was added as IS 
(RT 3.95 min; MRM 795.496 → 197.112).
 
Figure 1b: Plasma sample without adding IS (CoQ9). The peak corresponding 
to CoQ9 is not detectable.
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(EDTA, heparin and sodium citrate), to assure the best specificity 
and chromatographic response. Treating plasma samples with EDTA 
another chromatographic peak was detected in the chromatogram 
either of CoQ10 or of CoQ9 (Figure 2).
In the case of heparin a cleaner chromatographic profile was 
obtained (Figure 3), but the highest sensitivity was obtained treating 
plasma samples with sodium citrate (Figure 4).
Method validation
Reference standard samples and QC samples were prepared in 
physiological solution because being CoQ10 an endogenous substance, 
it is impossible to have blank matrices to be spiked. Specificity of the 
LC/MS-MS was evaluated by repeatedly extracting and analyzing 
250 µL of plasma spiked with IS (100 µL, 1 µg/mL), checking the 
presence of interfering peaks for each MRM at the retention time of the 
investigated compounds. 
For the study of linearity, calibration curves were performed 
by spiking 250 µL of physiological solution with six increasing 
concentration levels (10, 25, 50, 100, 200, 300 ngtot) of CoQ10. Analyses 
were carried out in triplicate. The linearity equation was y=3.49 × 10-2 
x+7.62 × 10-3 (R²=0.9927) indicating a good linearity of the method. 
The intercept was not significant as toss<ttab (toss=1.874; ttab=2.07; P<0.05).
LOQ was considered as the lowest concentration in which linearity 
was still satisfied, having a signal to noise ratio of at least 10. LOQ was 
10 ngtot of CoQ10. LOD, defined as the lowest concentration of analyte 
that can be clearly detected, is estimated as three times the signal to 
noise ratio. The LOD was determined by progressively diluting the 
solution prepared for the determination of the LOQ and resulted to 
be 5 ngtot.
Accuracy and repeatability were assessed determining the 
Response Ratio (RR) as follows. Working standards samples (WSS) 
were prepared and analyzed to determine RAstd defined as:
RAstd=Astd/AIS
Where Astd is the area of the peak of the quantifier MRM transition 
of the WSS; AIS is the area of the peak of the quantifier MRM transition 
of the IS.
Then for each solution the response ratio RR was calculated as: 
RR=RAstd / Cstd
Where Cstd is the concentration of the WSS (ng/mL)
Accuracy was evaluated as % recovery according to the following 
formula: 
%REC=(analytical concentration/ real concentration) × 100
Where the analytical concentration of CoQ10 calculated on the 
basis of the RRmean was then determined as the mean of the six RR 
obtained for the calibration curves. The real concentration is the 
effective concentration of CoQ10 present in each sample.
Three different solutions were analyzed in triplicate (50, 100, 200 
ngtot of CoQ10 in 250µL of physiological solution). % REC ranged from 
91.5 to 99.7% (%CV 4.3%), showing a good degree of accuracy of the 
method.
Intra-day precision was evaluated analyzing on the same day three 
different standard solutions at a concentration of 25 ngtot and 100 ngtot 
and calculating the %CV, which ranged from 3.0 to 4.0. Inter-day 
precision was assessed analyzing on six different days three different 
standard solutions at a concentration of 25 ngtot and 100 ngtot and 
calculating the %CV, which ranged from 15.9 to 4.8.
The calculation of the concentration of the analytes was obtained 
from the contemporary analysis of three QC (100 ngtot) always applying 
the following formula: 
Cx=RAsample/RRmean
where RRmean is the mean of the response ratio obtained for the 
three QC.
Stability of CoQ10 in plasma samples
Stability of CoQ10 in plasma samples was deeply investigated. First 
of all six QC samples (100 ngtot) were analyzed to evaluate repeatability 
and %CV was 6.93%.
Then CoQ10 stability in plasma samples stored at -20°C and 4°C 
was determined. A pool of frozen plasma samples were mixed and 
divided in six aliquots. Every aliquot was further divided in two parts: 
 
Figure 2: Chromatogram of a plasma sample treated with EDTA.
 
Figure 3: Chromatogram of a plasma sample treated with heparin.
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one stored at -20°C and the other heated at 4°C. In the case of samples 
stored at -20°C a mean concentration of 364.41 ng/mL was obtained 
(standard deviation: 18.54; %CV 5.09), while in the case of samples 
stored at 4°C a mean concentration of 402.37 ng/mL was obtained 
(standard deviation: 41.99; %CV 10.44).
As it is possible to note the variability in CoQ10 concentration 
is higher in the case of the samples heated at 4°C (% CV 10.44% and 
5.09 respectively), but the CoQ10 concentration resulted higher in 
these samples (mean concentration 402.37 ng/mL), respect to that 
of the samples stored at -20°C (mean concentration 364.41 ng/mL). 
So to confirm the stability at 4°C we decided to analyze one plasma 
sample belonging to one volunteer, divided into five aliquots (Table 
2), which were not frozen and in this case we obtained a lower %CV 
demonstrating that the conservation at 4°C is suitable for CoQ10 
analysis. The higher variability of the CoQ10 concentration at 4°C 
respect to the lower variability at -20°C reported before was therefore 
probably due to the fact that the plasma samples were initially frozen 
and then cooled to 4°C.
To evaluate long term stability five plasma samples were taken into 
account. After being analyzed, they were stored at 4°C and analyzed 
after 8 months. The t-test was performed (Table 3), showing that 
the two series of data are not statistically different (P<0.05), so we 
concluded that storing the samples at 4°C is a suitable way to preserve 
CoQ10 even for a long period of time.
In this way we demonstrated that it is not necessary to store plasma 
sample at -20 or -80°C as stated in the literature [1,4,8] for the analysis 
of CoQ10, thus simplifying the analytical procedure. In fact the analysis 
of frozen samples is more difficult and longer. 
Analysis of plasma samples of healthy volunteers
Nine healthy volunteers were monitored for 11 days. Their plasma 
was analyzed before the treatment (day 1, day 4) and the mean value 
of CoQ10 concentration was calculated. Then they were supplied with 
a food supplement containing CoQ10 for 7 days and at the end of the 
treatment their plasma (day 11) was analyzed. Results are reported in 
Table 4 and Figure 5.
The volume of plasma used for the extraction was 250 µL; in the 
cases in which the CoQ10 concentration exceeded the linearity range 
a second determination was carried out starting from 100 µL. In this 
way the CoQ10 concentration fell inside that of the calibration curve.
The series of data were statistically different (P<0.05) at the end 
of the supplementation of CoQ10. The increment of the plasma 
concentration of CoQ10 was calculated and in all volunteers there was 
a significant increment. This demonstrates that the assumption of a 
food supplement containing CoQ10 could be of help in increasing its 
plasma concentration in a significant way, affording all the beneficial 
properties of this ubiquinone.
Conclusion
The validated UPLC/MS-MS method for the determination of 
CoQ10 in human plasma was applied to the analysis of plasma samples 
belonging to nine people assuming food supplements containing 
CoQ10, in order to evaluate the increase of ubiquinone concentration 
in plasma after oral intake. The concentration of CoQ10 after the 
supplementation resulted significantly higher in all volunteers, 
indicating that assuming food supplements containing CoQ10 could 
be of help for increasing its concentration in plasma to exploit all the 
beneficial properties of this ubiquinone.
Analyte Precursor ion (m/z)
Product ion 
(m/z) Dwell ms Cone (V)
Collision 
(eV)
CoQ10 863.60 197.17 0.025 42 38
CoQ10 863.60 81.12 0.025 42 66
CoQ10 863.60 95.16 0.025 42 70
CoQ9 795.49 197.11 0.025 34 32
Table 1: MRM transitions for CoQ10 and CoQ9 (IS).
CoQ10 Concentration (ng/mL) Mean STD %CV
497.56 497.56 26.13 5.25
492.43
518.62
538.20
469.73
Table 2: Concentration of CoQ10 in plasma sample stored at 4°C.
Volunteer Initial concentration (ng/mL) After 8 months (ng/mL)
1 379.6 419.9
2 610.0 658.1
3 474.2 485.7
4 373.7 413.3
5 179.5 208.9
Table 3: Stability of CoQ10 in fresh plasma samples of five volunteers stored at 
4°C.
Figure 4: Chromatogram of a plasma sample treated with sodium citrate.
Volunteer Day 1 Day 4 Mean day 1- 
Day 4
Day 11 % Increment
1 (F) 669.8 791.9 730.8 1110.4 51.9
2 (F) 998.5 1218.0 1108.2 1537.1 38.7
3 (M) 667.1 665.7 666.4 1368.7 105.4
4 (F) 561.3 582.0 571.6 1005.3 75.9
5 (F) 872.9 949.2 911.0 1115.6 22.4
6 (F) 1089.8 1248.1 1168.9 2012.6 72.2
7 (F) 806.7 852.0 829.3 1926.0 132.2
8 (M) 1387.8 1644.6 1516.2 1827.6 20.5
9 (M) 1291.9 1877.0 1584.4 1874.6 18.3
Table 4: Plasma concentration (ng/mL) and increment of CoQ10 before (day 1, day 
4) and after (11 days) the supplementation of nine healthy volunteers (F=Female; 
M=Male).
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Figure 5: CoQ10 concentration (ng/mL) of the volunteers before (Mean day 
1-day 4), and at the end (day 11) of the treatment.
